The following letter was submitted to The Montana Standard from Butte-Silver Bow Chief Executive J.P. Gallagher. Writing on ...

A group of faith leaders, community advocates, and activists continues to call on the Monroe County District Attorney's ...

The Adelaide mom is met with sympathy, her husband with praise and both of them cop opinions that belong back in 1963. She’s ...

Both Emanuel Colombini and yours truly had a poster of a Lamborghini Diablo on our respective bedroom walls. However, only one of us made that childhood dream come true: not just by owning a Diablo, ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

There had been a fleeting window of sympathy, and then the story flipped. Israel’s military steps became the headline—its ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

ICE raids are disrupting worksites across the country, particularly construction sites, as President Trump’s mass deportation ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...